MBRS-30. TORC1/2 INHIBITION SENSITIZES MYC-DRIVEN MEDULLOBLASTOMA CELLS TO CARBOPLATIN CHEMOTHERAPY
Rachael Maynard(Johns Hopkins University), Eric H. Raabe(Johns Hopkins University), Scott L. Pomeroy(Broad Institute), Charles G. Eberhart(The University of Texas MD Anderson Cancer Center), Tenley C. Archer(Georgetown University), Bradley Poore(University of Pittsburgh), Jeffrey Rubens(Johns Hopkins University), Allison R. Hanaford(Johns Hopkins Medicine), Pablo Tamayo(Dana-Farber Cancer Institute)
Cited by 0
Related Papers
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
|Proceedings of the National Academy of Sciences|2005|56.5k
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
|Science|1999|11.6k
PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
|Nature Genetics|2003|10.6k
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k